With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
Hosted on MSN9d
FDA CDER director Patrizia Cavazzoni announces resignationFollowing a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
MATTB provides assistance and training through outreach to industry. A: CDER's Division of Drug Information (DDI) serves as a focal point for public inquiries regarding human drug products.
M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER), regarding the proposal. Before the FDA’s proposal, several experts had set in motion the questioning of its ...
The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback